Literature DB >> 9564198

Reliability and validity of the SKAMP rating scale in a laboratory school setting.

S B Wigal1, S Gupta, D Guinta, J M Swanson.   

Abstract

In children with attention deficit hyperactivity disorder (ADHD), the effects of methylphenidate were investigated in a pharmacodynamic comparison of placebo and the standard b.i.d. administration of methylphenidate. In each of these conditions, teachers completed ratings in classroom settings at times chosen to coincide with expected "peaks" and "troughs" of serum concentrations in the b.i.d. condition. Analyses of variance (ANOVAs) revealed the expected differences between the two conditions in the laboratory classroom setting using standard rating scales (Conners and the IOWA Conners) and a new rating scale (the SKAMP), which specifically measures the classroom manifestation of ADHD. The psychometric properties of the SKAMP were evaluated by calculating test-retest reliability and by calculating correlations with the standard rating scales to establish concurrent validity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564198

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  46 in total

1.  Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.

Authors:  David W Goodman
Journal:  P T       Date:  2010-05

2.  Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Tim Wigal; Sabrina Schuck; Matthew Brams; David Williamson; Robert B Armstrong; H Lynn Starr
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-13       Impact factor: 2.576

3.  [Prevalence of and screening for ADHD in Costa Rica].

Authors:  Mónica Berrocal; Viviana Peskin; Nicholas Weiss; Jovita Schuler; Silvia Monge; James J McGough; Denise Chavira; Mónica Bagnarello; Luis D Herrera; Carol A Mathews
Journal:  Vertex       Date:  2011 Sep-Oct

4.  ADHD: Is Objective Diagnosis Possible?

Authors:  C Thomas Gualtieri; Lynda G Johnson
Journal:  Psychiatry (Edgmont)       Date:  2005-11

Review 5.  A Review of the Clinical Utility of Systematic Behavioral Observations in Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Franziska Minder; Agnieszka Zuberer; Daniel Brandeis; Renate Drechsler
Journal:  Child Psychiatry Hum Dev       Date:  2018-08

6.  Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

Authors:  Jeffery N Epstein; Margaret D Weiss
Journal:  Prim Care Companion CNS Disord       Date:  2012-11-29

7.  Chiropractic care for paediatric and adolescent Attention-Deficit/Hyperactivity Disorder: A systematic review.

Authors:  Fay Karpouzis; Rod Bonello; Henry Pollard
Journal:  Chiropr Osteopat       Date:  2010-06-02

Review 8.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.

Authors:  Sharon B Wigal; Ann C Childress; Heidi W Belden; Sally A Berry
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-01-05       Impact factor: 2.576

10.  A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Scott H Kollins; Ann C Childress; Liza Squires
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-06-09       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.